Publication: Statin Effects to Reduce Hepatosteatosis as Measured by Computed Tomography in Patients With Human Immunodeficiency Virus
Loading...
Open/View Files
Date
2016
Published Version
Journal Title
Journal ISSN
Volume Title
Publisher
Oxford University Press
The Harvard community has made this article openly available. Please share how this access benefits you.
Citation
Lo, Janet, Michael T. Lu, Elli A. Kim, Eric Nou, Travis R. Hallett, Jakob Park, Udo Hoffmann, and Steven K. Grinspoon. 2016. “Statin Effects to Reduce Hepatosteatosis as Measured by Computed Tomography in Patients With Human Immunodeficiency Virus.” Open Forum Infectious Diseases 3 (2): ofw062. doi:10.1093/ofid/ofw062. http://dx.doi.org/10.1093/ofid/ofw062.
Abstract
Hepatosteatosis is highly prevalent among patients living with human immunodeficiency virus. In a 1-year, randomized, double-blind trial of atorvastatin or placebo, atorvastatin increased liver/spleen ratio among patients with nonalcoholic fatty liver disease, indicating a reduction in hepatosteatosis. This reduction in hepatosteatosis is associated with reduction in low-density lipoprotein cholesterol with statin therapy.
Description
Other Available Sources
Research Data
Keywords
hepatosteatosis, human immunodeficiency virus, LDL cholesterol, statin
Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material (LAA), as set forth at Terms of Service